MEFLOQUINE TABLET

Country: Կանադա

language: անգլերեն

source: Health Canada

active_ingredient:

MEFLOQUINE (MEFLOQUINE HYDROCHLORIDE)

MAH:

AA PHARMA INC

ATC_code:

P01BC02

INN:

MEFLOQUINE

dosage:

250MG

pharmaceutical_form:

TABLET

composition:

MEFLOQUINE (MEFLOQUINE HYDROCHLORIDE) 250MG

administration_route:

ORAL

units_in_package:

8

prescription_type:

Prescription

therapeutic_area:

ANTIMALARIALS

leaflet_short:

Active ingredient group (AIG) number: 0124227001; AHFS:

authorization_status:

APPROVED

authorization_date:

2010-05-26

SPC

_Product Monograph MEFLOQUINE _
_ _
_Page 1 of 39_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
MEFLOQUINE
Mefloquine Tablets
250 mg Mefloquine (as Mefloquine Hydrochloride)
ANTIMALARIAL AGENT
AA Pharma Inc.
1165 Creditstone Road, Unit#1
Vaughan, Ontario
L4K 4N7
Date of Revision:
September 20, 2017
Submission Control No: 206824
_ _
_Product Monograph MEFLOQUINE _
_Page 2 of 39 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................17
STORAGE AND STABILITY
..........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
...............................................................................18
PHARMACEUTICAL INFORMATION
..........................................................................19
CLINICAL TRIALS
............................................................................................